Gossamer Bio (GOSS) to Release Quarterly Earnings on Tuesday

Gossamer Bio (NASDAQ:GOSS - Get Free Report) is expected to release its Q1 2025 earnings data before the market opens on Tuesday, May 6th. Analysts expect Gossamer Bio to post earnings of ($0.19) per share and revenue of $3.95 million for the quarter.

Gossamer Bio (NASDAQ:GOSS - Get Free Report) last announced its quarterly earnings data on Tuesday, March 18th. The company reported ($0.15) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.15). The company had revenue of $9.38 million for the quarter, compared to the consensus estimate of $7.02 million. On average, analysts expect Gossamer Bio to post $0 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Gossamer Bio Stock Up 3.9 %

Shares of NASDAQ GOSS traded up $0.04 during trading hours on Thursday, hitting $1.06. The company had a trading volume of 1,783,985 shares, compared to its average volume of 1,584,086. The stock has a market capitalization of $240.85 million, a P/E ratio of -3.31 and a beta of 1.88. Gossamer Bio has a 1-year low of $0.50 and a 1-year high of $1.55. The firm's 50 day moving average is $1.07 and its 200-day moving average is $0.98. The company has a quick ratio of 6.74, a current ratio of 6.74 and a debt-to-equity ratio of 3.64.

Hedge Funds Weigh In On Gossamer Bio

A hedge fund recently raised its stake in Gossamer Bio stock. Bank of America Corp DE grew its stake in Gossamer Bio, Inc. (NASDAQ:GOSS - Free Report) by 107.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 84,788 shares of the company's stock after purchasing an additional 43,866 shares during the quarter. Bank of America Corp DE's holdings in Gossamer Bio were worth $77,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 81.23% of the company's stock.

Analysts Set New Price Targets

A number of brokerages have commented on GOSS. The Goldman Sachs Group cut their price target on shares of Gossamer Bio from $8.00 to $7.00 and set a "buy" rating for the company in a research note on Thursday, April 17th. HC Wainwright reiterated a "buy" rating and issued a $10.00 price target on shares of Gossamer Bio in a research note on Tuesday, March 18th. Finally, Wedbush reiterated an "outperform" rating and issued a $4.00 price target on shares of Gossamer Bio in a research note on Friday, March 14th.

About Gossamer Bio

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.